Ranbaxy launches generic Clarithromycin in Japan

Nihon Pharmaceutical Industry (NPI), a joint venture of Ranbaxy Laboratories and Nippon Chemiphar, has successfully launched the generic versions of Clarithromycin 50mg & 200mg tablets and Terbinafine 125mg tablets.

According to a release issued by Ranbaxy to the BSE today, Clarithromycin is an anti-biotic and Terbinafine an anti-fungal with a market size of around $400 million and $300 million, respectively, in Japan for the above dosage forms.

"The products will be sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry label, and will be marketed and actively promoted to doctors in hospitals as well as clinics jointly by the field forces of NC and NPI," the release added.

Malvinder Mohan Singh, CEO & managing director of Ranbaxy, said: "It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio."